8212- Preserved: CDR132L in people with heart failure with preserved ejection fraction

• Research type

  Research Study

• Full title

  Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy

• IRAS ID

  1011245

• Contact name

  Clinical Transparency

• Contact email

  clinicaltrials@novonordisk.com

• Sponsor organisation

  Novo Nordisk A/S

• Eudract number

  2024-515796-35

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  Not available

• Research summary

  We are doing this study to see how the new medicine, called CDR132L, works on the structure and function of the heart in people living with heart failure. Heart failure is a condition in which the heart muscle is unable to pump enough blood to meet the body’s needs. If the heart pumps normally, but is too stiff to fill properly, the condition is known as heart failure with preserved ejection fraction (HFpEF). Some people develop harmful changes in the heart muscle, and heart tissue can stiffen and get too thick (also known as left ventricular hypertrophy). No medicine exists that aims to improve these specific changes in the heart muscle.

• REC name

  Wales REC 2

• REC reference

  25/WA/0022

• Date of REC Opinion

  27 Mar 2025

• REC opinion

  Further Information Favourable Opinion